A Study Comparing Efficacy and Tolerance of Two Maintenance Strategies : a Monotherapy With Lopinavir/Ritonavir or a Single-tablet Triple Therapy by Efavirenz/Emtricitabin/Tenofovir in HIV-1 Infected Patients With HIV RNA Below 50 cp/mL.

Trial Profile

A Study Comparing Efficacy and Tolerance of Two Maintenance Strategies : a Monotherapy With Lopinavir/Ritonavir or a Single-tablet Triple Therapy by Efavirenz/Emtricitabin/Tenofovir in HIV-1 Infected Patients With HIV RNA Below 50 cp/mL.

Completed
Phase of Trial: Phase II/III

Latest Information Update: 23 Mar 2018

At a glance

  • Drugs Lopinavir/ritonavir (Primary) ; Efavirenz/emtricitabine/tenofovir-disoproxil-fumarate
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms DREAM
  • Most Recent Events

    • 23 Mar 2018 According to results published in the Journal of Antimicrobial Chemotherapy, because of slow recruitment, the trial steering committee decided to terminate inclusions after a 7 month extension of the initial 12 month inclusion period.
    • 23 Mar 2018 Primary endpoint (Proportion of patients without treatment failure at Week 96: non-inferiority against Atripla in primary analysis population (n=195)) has not been met, according to results published in the Journal of Antimicrobial Chemotherapy.
    • 23 Mar 2018 Results published in the Journal of Antimicrobial Chemotherapy.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top